SUMMARY Preliminary results in vitro have indicated that carbenoxolone and analogues possessed activity against herpes viruses. We undertook a double blind clinical study to compare the efficacy of carbenoxolone and cicloxolone creams with placebo in initial and recurrent herpes genitalis. Seventy-nine patients (21 of whom were entered in the trial more than once) received 105 courses of treatment, 83 of which were suitable for life table analysis. There were significant differences in the time to disappearance of pain (p = 0' 044) and the healing of lesions (p = 0 023) in favour of cicloxolone compared with placebo. Carbenoxolone showed some beneficial effect compared with placebo, but this was not significant. Results on day 5 were similar. The only adverse reaction was mild erythema with irritation in one patient in each treatment group. We conclude that further trials with more extensive virological investigation are indicated to confirm the beneficial effect of cicloxolone.
Introduction
In an earlier study of balanitis, some cases of which were associated with herpes simplex, it was found that the topical application of carbenoxolone sodium gel (2%) gave promising results.' This compound was chosen because of its reported efficacy in healing ulcers and erosions of mucous membranes. It was later decided to try topical carbenoxolone and the chemically related cicloxolone in an open study of patients with confirmed herpes genitalis. The results showed that the preparations speeded healing both in initial and recurrent attacks. As herpes genitalis has a notoriously unpredictable course and the placebo effect can be as high as 607o, we undertook a double blind placebo controlled trial.
LABORATORY ANTIVIRAL STUDY
In a preliminary study, carbenoxolene and some close analogues were tested for antiviral effects in tissue culture. The drugs were administered in the presence of albumin and diluted with maintenance medium. The drugs were tested in cultures of Hela Address for reprints: Dr G W Csonka, John Hunter Clinic, St Stephen's Hospital, Fulham Road, Chelsea, London SWIO 9TH Accepted for publication 24 November 1983 cells or human fibroblasts (MRC 5) which were challenged with about 1000 median tissue culture dose of recently isolated herpes simplex viruses and observed for three days. The drugs, which were at high concentrations, appeared to be rather toxic and caused the cells to 'round up' in the absence of virus. With some analogues at sub-toxic concentrations, however, the viral effect was delayed or prevented. An antiviral effect was seen with carbenoxolone 10-4 mol/l against an oral strain, and 10-3 5 mol/l against a genital strain. Other analogues of carbenoxolone were also active against the oral strain. By ordinary criteria, however, these substances would have been regarded as too toxic in vitro, even when protein bound, to warrant further testing. As We intended to take samples for culture every other day until the lesions were healed. Data on the type, site, and extent of lesions and the presence or absence of prodromal symptoms were noted, as were the date of onset of symptoms, the date when the cream was first applied, the times to the disappearance of itching and of pain, and the times to crusting and complete healing. The severity of symptoms and lesions were assessed at each visit on a four point scale (for lesions: 1 = severe, 2= moderate, 3 = mild, 4= absent; for symptoms: 1 = worse, 2= same, 3 = mild, 4= absent). Side effects were enquired into and recorded. After the lesions had healed the patients were asked for their assessment of the treatment.
The medicated cream contained either 2% carbenoxolone sodium or 2% cicloxolone sodium; the control cream was of the same formula but contained neither test medication (Biorex Laboratories Limited). The creams were dispensed in numbered 15 g tubes. Patients were instructed to apply the preparation sparingly to the lesions five times a day for seven days, or for the the duration of the lesions and for 24 hours after healing, whichever was the shorter period. They were asked to attend on alternate days for the first four to six days, on day 7 and day 14 after the start of treatment, and at any time if the lesions did not heal or if new lesions developed during the period of the trial. Swabs were taken for confirmation of the presence of HSV at each attendance while the lesions were present.
Of the 79 patients entered into the study, 21 were entered again with further attacks (four of them were entered more than twice). They then received another randomised tube of cream. Each treatment period was counted as a separate and distinct "patient". Ten patients were excluded from the analysis due to late entry or inadequate viral confirmation, one patient was excluded because of misdiagnosis, and 11 patients defaulted, making a total of 22 exclusions. Patients in the three treatment groups showed a similar distribution as regards age, marital status, socioeconomic group, and frequency of past attacks of herpes genitalis.
Results Table I shows that the number of patients with initial or recurrent herpes genitalis in each of the three treatment groups was similar. Of the 19 patients with initial attacks of herpes genitalis, 11 could be fully analysed. Some patients had more than one attack during the six month study period and of the 86 recurrent episodes, 56 had a positive viral culture on entry and 83 were analysed. Table II shows the results at the end of the study. The mean score for severity of lesions before treatment in all patients with recurrent attacks was 2-18 in the carbenoxolone group, 2-17 in the cicloxolone group, and 1-93 in the placebo group. 2) included above n = total number of patients complying with protocol including defaulters. G WCsonka and D A J Tyrrell expected to heal spontaneously by the tenth day in most patients, we decided to analyse the results obtained at five days before decoding the study. Patients who defaulted before day 5 were excluded from this analysis. Fisher's exact probability test was used to analyse the differences between carbenoxolone, cicloxolone, and placebo in (a) patients with recurrent herpes genitalis and (b) the combined group with initial and recurrent herpes genitalis, as the number of patients with an initial attack was too small for separate statistical analysis. Table III shows that, although carbenoxolone gave some benefit in the treatment of herpes genitalis this was not significant. Cicloxolone was significantly better than placebo in both the recurrent and the combined groups. Cicloxolone was also more effective than carbenoxolone. Thus comparison of cicloxolone with carbenoxolone in this relatively small group of patients showed a difference in favour of cicloxolone, although this was not significant at the conventional level.
ASSESSMENT BY PATIENTS About three quarters of the patients with recurrent attacks who had experience with other treatments, including topical acyclovir, thought that the test preparations gave a more rapid relief from discomfort. 
